New agreement allows Minbos to develop fertilizer market in Angola

|

Published 11-DEC-2020 12:19 P.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Minbos Resources Limited (ASX:MNB) and the International Fertilizer Development Centre (IDFC) have implemented a Memorandum of Understanding (MOU) to develop and grow the Small Holder Farmer market in Angola.

The IFDC is an international non-for-profit organisation, dedicated to scientific innovations that increase global food production, protect the environment and empower Small Holder Farmers.

In improving the lives and productivity of Small Holder Farmers, the IFDC runs country-scale agricultural projects across Africa which introduces farmers to improved agricultural practises, fertiliser technologies and facilitation of market access.

Minbos has worked collaboratively with the IFDC for several years, helping to develop the company’s Cabinda Phosphate Product, most notably in developing market demand in one of the most prospective fertiliser regions globally.

The new MOA provides the platform to develop a joint proposal for a multi-year project designed to support the development of the local fertiliser market in Angola.

Angola is one of the world’s great untouched agricultural regions, possessing over 35 million hectares of arable land, high rainfall and some of the lowest rates of fertiliser use globally.

Minbos hopes to leverage the IFDC’ innovative research and market expertise to identify sustainable solutions for soil and plant nutrition for the benefit of Small Holder Farmers, local communities and the environment.

Utilising strategic partners, the IFDC works with national and private parties to create or expand Small Holder fertiliser demand in parts of Angola.

Productivity gains are predicted to cause marketable crop surpluses, encouraging additional farmer investment in fertilisers.

More than four million Small Holder Farmers are expected to be reached by the IFDC Angola project, which will be underpinned by Minbos' fertiliser production.

The Cabinda Phosphate Project will commence production at 50,000tpa. Given the large Small Holder Farmer market in Angola and the IFDC’s strong record of delivering high-impact projects which boost fertiliser usage, demand is expected to exceed the nameplate capacity of 150,000tpa.

Commenting on the MOU, Minbos CEO Linday Reed said, “As the Company looks to enter production in early 2022, securing market offtake through a program that unlocks value for local Small Holder Farmers and government stakeholders, as well as Minbos shareholders, is key to our successful collaboration.

"This first step in developing a project to establish a new market in Angola marks another milestone for Minbos as we look towards production in early 2022.”



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X